Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Collaboration for Radiotherapy Microphere Drug Development for the Treatment of Primary and Secondary Liver Cancer

By BiotechDaily International staff writers
Posted on 31 Mar 2014
Sirtex Medical, Ltd. (Sydney, Australia) and Guerbet, SA (Villepinte, France) are entering into a clinical studies collaboration in primary and secondary (metastatic) liver cancer.

The aim of the collaboration is to examine how Sirtex’s SIR-Spheres microspheres and Guerbet’s Lipiodol Ultra Fluid may be combined or sequenced optimally—and additionally developed—for the treatment of patients with hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and a variety of other primary and secondary liver cancers.

Sirtex’s chief executive officer, Gilman Wong commented that, “Sirtex’s and Guerbet’s shared vision is that one day, rather than being a terminal disease that patients unfortunately die from, liver cancer may be considered a chronic disease that patients can successfully live with. During my time at Sirtex, I have been fortunate to meet a number of patients who have survived their liver cancer for many years following treatment with SIR-Spheres microspheres. We hope through this clinical studies collaboration to make further gains for the benefit of the patients afflicted by liver cancer. Should the initial collaboration prove fruitful, future collaborations in R&D and marketing between our respective companies may be considered.”

Sirtex’s SIR-Spheres microspheres are utilized in selective internal radiation therapy (SIRT), also known as radioembolization, for the treatment of patients with inoperable liver tumors. SIR-Spheres microspheres have been shown in randomized controlled trials (RCTs) to optimize survival in patients with inoperable liver metastases from primary colorectal cancer. SIR-Spheres microspheres are now being assessed in six international, multicenter RCTs in metastatic colorectal cancer (mCRC) and hepatocellular carcinoma (HCC), which cumulatively will enroll over 2,100 patients. The first of these RCTs, the SIRFLOX study, finished patient enrolment in April 2013 and is expected to report its findings in early 2015.

Guerbet’s Lipiodol Ultra Fluid is used in traditional transarterial chemo-embolization (cTACE) procedures for the treatment of patients with inoperable liver tumors. cTACE has been published in over 100 clinical studies. Recently, cTACE has been established as the standard-of-care for the treatment of patients with intermediate stage HCC by three international clinical consensus guidelines in Europe, Japan, and the United States. These consensus guidelines universally recommend cTACE as the standard-of-care for patients with intermediate stage HCC.

Guerbet’s chief executive officer, Yves L’Epine, said, “We are excited about the potential of combining or sequencing our products to improve the efficacy of interventional radiology procedures in patients with unresectable hepatic tumors. Indeed, while Lipiodol and SIR-Spheres individually are well proven and widely used therapies in their own right, they have never been formally evaluated together or sequentially.”

Guerbet is a pharmaceutical group focused on contrast imaging development, offering of contrast products for X-ray and MRI and for interventional radiology, along with a range of injectors and related medical equipment to provide enhanced diagnosis and treatment of patients.

Related Links:

Sirtex Medical
Guerbet 



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.